StockNews.AI
GERN
StockNews.AI
197 days

Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

1. Geron will release Q4 2024 financial results on February 26, 2025. 2. The conference call will discuss financial results and business highlights. 3. Geron's telomerase inhibitor RYTELO is approved for lower-risk MDS treatment. 4. A Phase 3 trial for R/R MF is in progress, showing potential market impact. 5. Webcast of the event will be available and archived on Geron's website.

Earnings
+2.15%Current Return
VS
+0.87%S&P 500
$2.7902/03 09:48 AM EDTEvent Start
$2.8502/03 08:08 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Geron's upcoming financial results could potentially reflect positive growth. Historical earnings releases often influence stock prices significantly.

How important is it?

The announcement relates directly to Geron's performance, potentially affecting investor confidence. Previous earnings releases indicate market sensitivity to such updates.

Why Short Term?

The financial release and conference call will provide immediate insight. Stock reactions to earnings reports are typically quick.

Related Companies

GERNIMETELSTAT
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights before the market opens on Wednesday, February 26, 2025 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time the same day. A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days. Participants may access the webcast by registering online using the following link, https://events.q4inc.com/attendee/332361629 About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

Related News